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Abstract
Background: Information on scintigraphy findings in dogs with thyroid neoplasia is
scarce. The use of single-photon emission computed tomography (SPECT) could
improve detection of metastatic disease.
Hypothesis/Objectives: To describe planar and SPECT imaging findings in dogs with
thyroid tumors, and to compare SPECT and thoracic radiography for metastasis
detection.
Animals: Sixty-eight dogs with thyroid neoplasia.
Methods: Retrospective study, search of medical records for dogs with thyroid neo-
plasia (2008-2018).
Results: Thyroid scintigraphy was available from 68 dogs, of which 6 presented after
surgical resection. Radionuclide uptake was increased in 56% of dogs, decreased in
24%, and comparable to that of the salivary glands in 13%. The remainder had multi-
ple masses with variable uptake. A homogeneous uptake pattern was present in 16%
and a heterogeneous uptake pattern in 73%. In 11% (all dogs with multiple masses),
various uptake patterns were present. Thyroid tumors were well delineated in 55%.
There was a significant association between hormone status and uptake pattern
(P = .009), with a heterogeneous uptake pattern in the majority of euthyroid dogs,
and hormone status and tumor circumscription (P = .003), with well-circumscribed
margins in the majority of hypothyroid and hyperthyroid dogs. Thoracic SPECT imag-
ing was available in 39 dogs and identified metastatic lesions in 15 dogs. Thoracic
radiographs were performed in 14 of these dogs, and detected metastases in 3 dogs.
Abbreviations: 123I, iodine-123; 131I, iodine-131; 99mTcO4, pertechnetate; CT, computed tomography; FTC, follicular cell thyroid carcinoma; IHC, immunohistochemistry; MBq, megabecquerel;
MTC, medullary thyroid carcinoma; SPECT, single-photon emission computed tomography; T/S ratio, thyroid to salivary gland ratio; TSH, thyroid-stimulating hormone; TT4, total thyroxine.
Received: 23 March 2020 Accepted: 15 September 2020
DOI: 10.1111/jvim.15908
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
J Vet Intern Med. 2020;34:2651–2659. wileyonlinelibrary.com/journal/jvim 2651
Conclusions and Clinical Importance: SPECT imaging is a viable imaging technique to
screen for thoracic metastasis and wider use of SPECT imaging is recommended in
dogs with thyroid neoplasia.
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1 | INTRODUCTION
Thyroid tumors are among the most common endocrine tumors in
dogs.1 The vast majority of thyroid tumors in dogs are malignant, and
16% to 60% of dogs have evidence of metastases at the time of diagno-
sis.1-3 Thyroid tumors can arise from follicular cells or from parafollicular
C-cells.2 Thyroid scintigraphy has an important added value in the diag-
nosis, staging, and treatment planning of thyroid carcinoma.4-6 It is used
to assess if a patient is a good candidate for radioiodine treatment and
can identify ectopic and metastatic thyroid tissue.4,6,7 Distant metasta-
ses can be detected with planar scintigraphy.7-11 In spite of this, planar
scintigraphy is usually inferior to radiographs or computed tomography
(CT) for the evaluation of pulmonary metastases.5,12 Radioiodine (123I
or 131I) might be superior to pertechnetate (99mTcO4) for detection of
small or low intensity uptake lesions (eg, thoracic metastases) because
of higher target-to-background ratios.4,5 However, 123I is considerably
more expensive than pertechnetate, which limits its use in veterinary
medicine. Although 131I is less expensive and readily available, its rela-
tively high radioactive burden to the patient, long half-life (8.1 days)
and poor imaging characteristics due to high energy γ-rays not ideally
suited to collimation by conventional gamma camera imaging, make it
unfavorable for routine scanning.4,6,13 Both pertechnetate and radio-
iodine (123I and 131I) are actively concentrated or trapped by the thyroid
gland, which is mediated by the sodium iodide symporter. However,
unlike stable iodine and radioiodine, pertechnetate is not organified or
incorporated into thyroid hormone by the thyroid gland, reflecting only
the trapping mechanism, and not the “true” uptake of the thyroid
gland.13,14 After intravenous administration of radionuclides, some vas-
cular activity inside the heart and blood vessels can be seen on scintig-
raphy, which is considered physiologic. Because this blood pool activity
can be confused with pathologic radionuclide uptake, it can result in
false-positive results for metastatic disease.15
In humans with well-differentiated thyroid carcinoma, planar 131I
whole-body scintigraphy is considered the routine diagnostic proce-
dure and is used in the detection of both residual thyroid tissue and
metastases for staging after thyroidectomy.16-18 Planar imaging, how-
ever, can give false-negative results for small metastatic lesions.
Single-photon emission computed tomography (SPECT) has higher
sensitivity and better contrast resolution than planar imaging, and can
obtain cross-sectional scintigraphic images, improving the detection
of metastases.4,16,17,19 The use of SPECT integrated with CT (SPECT/
CT) systems provides an incremental value in staging and clinical man-
agement of humans with thyroid neoplasia because it provides more
correct anatomic localization and characterization of abnormal foci of
radioiodine uptake.16-18,20 However, to the authors' knowledge, this
technique has not been described in veterinary medicine.
The aim of this retrospective study was to describe planar and
SPECT imaging findings in dogs with thyroid neoplasia, and to compare
SPECT with thoracic radiography for detection of thoracic metastases.
2 | MATERIALS AND METHODS
2.1 | Case selection
Medical records of dogs referred to the Clinic of Small Animals of
Ghent University for suspected or confirmed thyroid neoplasia between
January 2008 and December 2018 were reviewed. All dogs had a con-
firmed diagnosis of thyroid neoplasia based on histopathology, cytol-
ogy, abnormal radionuclide accumulation, or a combination of these.
Dogs without scintigraphic examination were excluded.
2.2 | Medical records review
Information obtained from the medical records included signalment,
clinical signs, physical examination findings, serum total thyroxine
(TT4) and thyroid-stimulating hormone (TSH) concentrations, results
of cytologic and histologic analyses and immunohistochemistry (IHC),
imaging results (cervical scintigraphy, thoracic SPECT, thoracic radio-
graphs, and CT), and treatment modality.
2.3 | Scintigraphy
Dogs were injected with a median activity of 98 MBq (range,
41-252 MBq) of 99mTcO4 (n = 53) or 37 MBq (range, 11-48 MBq) of
123I
(n = 17) via an intravenous catheter. Thyroid scans were acquired 20 to
30 minutes after injection with 99mTcO4, and 24 hours after injection
with 123I. A single static count based image (200 kcounts) was acquired
with the dogs positioned in ventral recumbency, on a gamma camera
equipped with a low energy high resolution collimator, located under-
neath the table (GCA 7200A; Toshiba, Tokyo, Japan). Matrix size was
256 × 256 and pixel size was 0.1 cm. Scan processing was performed
using multimodality software (Hermes V5.0; Nuclear Diagnostics AB,
Northfleet, UK). After the static acquisition, with the dogs remaining
in ventral position, SPECT data of the thoracic area were acquired
with a dual head gamma camera (GCA 7200A; Toshiba) equipped with
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low-energy high resolution parallel hole collimators (tomographic resolu-
tion full width at half maximum = 9 mm). Data were acquired over a cir-
cular 360 rotation, for 20 minutes in step-and-shoot mode (120 steps,
10 seconds per step, 3 per step) on a 128 × 128 matrix. Images were
then processed using iterative reconstruction and a Butterworth filter
(cut-off 1.4 cycli/cm, order 5). Pixel size was 1.72 mm.
In 8 dogs, scintigraphy was performed at a referring institution.
For these dogs, planar scans were available for interpretation.
Thyroid scintigraphy was used to determine the location and
radionuclide uptake of thyroid tumors. Compared to clinically healthy
dogs, in which the appearance of the thyroid glands is characterized
by homogeneous, symmetrical uptake by paired, oval thyroid lobes
with smooth and regular margins in the midcervical area,4,5,8 the
appearance of thyroid tumors was characterized by abnormal size and
shape of the thyroid lobe(s), abnormal location of radionuclide uptake,
and/or abnormal radionuclide uptake and uptake pattern.
The thyroid to salivary gland (T/S) ratio was calculated as the ratio
of the mean counts per pixel of the thyroid region of interest to the
mean counts per pixel of the ipsilateral parotid salivary gland region of
interest. In case of a unilateral thyroid tumor, calculations were made
for the affected thyroid lobe only, using the ipsilateral parotid salivary
gland. In case of bilateral thyroid tumors, T/S ratios were determined
separately for both thyroid lobes. For ectopic thyroid tumors, the T/S
ratio was calculated using the average of the ratios compared to both
parotid salivary glands.
Uptake patterns were described as (a) diffuse homogeneous radio-
nuclide uptake throughout the thyroid tumor; and (b) irregular, hetero-
geneous uptake, which could be diffuse or could show (multi)focal
areas of radionuclide accumulation with areas of increased and/or
decreased uptake. The tumors were also characterized by their margins,
with tumors having well-defined or ill-defined margins. Foci of uptake
in the salivary glands and stomach were considered physiologic.
All images obtained by both planar acquisition and SPECT were
analyzed by 1 board-certified radiologist with extensive experience in
nuclear medicine (K. Peremans) who was unaware of the clinical find-
ings, of any other diagnostic imaging data, and of the histopathologic
diagnosis.
2.4 | Metastasis screening
Digital radiographic images (DDR, Eklin Medical Systems, Santa Clara,
California) of the thorax, consisting of 2 or 3 views (right laterolateral,
left laterolateral, and ventrodosal views), were reviewed for the pres-
ence of metastases. A high kilovoltage peak and low milliampere-
seconds technique was used, with exact values based on body size of
the dog. For 4 dogs, thoracic radiographs were performed at a refer-
ring institution. For these dogs, digital radiographic images were avail-
able for interpretation.
Computed tomography images were obtained in sternal recum-
bency, in breath-hold mode, using a 4-slice helical CT device (Lightspeed
Qx/I, General Electric Medical Systems, Chicago, Illinois). Contiguous
slices were acquired at 2.5 mm thickness, 120 kV peak, 140 mA s,
with an image matrix of 512 × 512. Computed tomography imaging
was performed precontrast and after intravenous administration of
nonionic ionated contrast medium Omnipaque (GE Healthcare BVBA,
Diegem, Belgium). The images were reconstructed using conventional
reconstruction algorithms (pulmonary and soft tissue algorithms). For
evaluating the lung parenchyma, a lung window (width of 1400
hounsfield units [HU], level of −500 HU) was used, whereas a soft tis-
sue window (width of 350 HU, level of 40 HU) was used for evalua-
tion of mediastinal structures. Individual reviewers could adjust the
window width and level of the images to personal preference.
Thoracic radiographs and CT images were reviewed by 2 radiolo-
gists (E. Stock and E. Vandermeulen), who were blinded to findings of
related imaging tests, and agreement was reached by consensus.
SPECT images were reviewed for metastases by 1 board-certified
radiologist with extensive experience in nuclear medicine (K. Peremans)
and results were compared to the medical records, of which the original
reader was variable (both board-certified radiologists and radiologists in
residency program training). In case of disagreement with the medical
records, a second board-certified radiologist (E. Stock) reviewed the
SPECT images, and agreement was reached by consensus.
2.5 | Statistical analysis
Analyzed variables consisted of tumor scintigraphic uptake (increased,
decreased, or comparable to the salivary gland based on visual evalu-
ation of the scintigraphy images and T/S ratio), tumor scintigraphic
uptake pattern (homogeneous or heterogeneous), tumor scintigraphic
margins (well-defined or ill-defined), hormone status (euthyroid if
serum TT4 was within reference range, hyperthyroid if serum TT4
was above reference range, and hypothyroid if serum TT4 was below
reference range and serum TSH was increased), and tumor type (fol-
licular cell thyroid carcinoma [FTC], medullary thyroid carcinoma
[MTC], or unspecified thyroid [adeno]carcinoma). To determine if
there were associations between variables (hormone status and
tumor scintigraphic uptake, uptake pattern, tumor margins, and tumor
type; tumor type and tumor scintigraphic uptake, uptake pattern, and
tumor margins), the Fisher's exact test was applied at the 5% signifi-
cance level using SAS Version 9.4 (SAS Institute, Inc, Cary, North
Carolina).
3 | RESULTS
3.1 | Study population
A total of 105 dogs suspected or confirmed to have thyroid carcinoma
were referred to our clinic during the study period. Of these, scintigra-
phy was performed in 75 dogs; however, 7 of 75 were excluded
because a diagnosis of thyroid neoplasia could not be confirmed (n = 6)
or scintigraphy images were not available (n = 1). The remaining 68 dogs
were included in the study. Diagnosis of thyroid neoplasia was con-
firmed with histopathology (n = 38) and/or cytology (n = 30) in the
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majority of cases. In 8 dogs, the diagnosis of having a thyroid tumor
was based on abnormal scintigraphy findings only.
Median age at the time of initial presentation was 9.8 years (range,
5.8-17.8 years). Median body weight was 23 kg (range, 3.1-67 kg). Of
these 68 cases, 50% were female (25 neutered, 9 intact) and 50% were
male (22 neutered, 12 intact).
Clinical signs at time of initial presentation included a palpable
cervical mass (n = 63), weight loss (n = 18), cough (n = 14), polyuria/
polydipsia (n = 13), respiratory signs (dyspnea, stridor; n = 9), dysphagia
(n = 8), polyphagia (n = 6), reduced appetite (n = 6), exercise intolerance
(n = 5), dysphonia (n = 4), weight gain (n = 2), regurgitation (n = 1),
vomiting (n = 1), and diarrhea (n = 1).
Of 56 tested dogs, TT4 concentrations were within reference
limits for 31 dogs and above reference range in 12 dogs. Nine dogs
were hypothyroid at the time of initial presentation (based on serum
TT4 concentrations below the reference range and increased serum
TSH concentrations). Four dogs had low serum TT4 and normal
serum TSH concentrations.








Unilateral 39 Increased 3.2 (1.1-12) 35 Homogeneous 10 Well-defined 33
Bilateral 14 Decreased 0.73 (0.36-0.90) 15 Heterogeneous 45 Ill-defined 27
Ectopic 10 Comparable to
salivary gland






Unilateral + ectopic 1 Multiple masses with
variable uptake
4
Bilateral + ectopic 1
Unclassifieda 3
Note: Values for T/S ratio are expressed as median and range.
Abbreviation: T/S ratio, thyroid to salivary gland ratio.
aTumor extent hindered accurate localization.
F IGURE 1 Ventral planar
scintigraphic images of thyroid tumors in
4 dogs 20 to 30 minutes after intravenous
injection with 99mTcO4, showing different
uptake patterns, uptake extent, and tumor
circumscriptions. A, Bilateral thyroid
tumors with a heterogeneous uptake
pattern, increased uptake, and regular
tumor margins; B, Well-circumscribed
ectopic thyroid tumor with
heterogeneous increased uptake; C,
Unilateral (left) thyroid tumor with
decreased homogeneous uptake and
poorly circumscribed tumor margins. The
tumor margin is manually outlined in the
magnified image; D, Bilateral thyroid
tumors with increased uptake. The left
thyroid tumor has a homogeneous uptake
pattern and is well delineated, whereas
the right thyroid tumor has a
heterogeneous uptake pattern and is
poorly circumscribed
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Of the 38 cases with histopathological reports (either after biopsy
[core needle, surgical] or thyroidectomy), 25 were FTCs (follicular
[n = 10], follicular-compact [n = 9], compact [n = 6]), and 5 were
MTCs. Of the remaining 8 tumors, 5 were reported as thyroid (adeno)
carcinoma, 2 tumors could not be classified with certainty, and 1 ade-
noma was identified.
3.2 | Thyroid scintigraphy
Thyroid scintigraphy was available from 68 dogs, of which 6 presented
to our clinic after surgical resection. Data regarding the tumor loca-
tion, tumor scintigraphic uptake, uptake pattern, and margins are pres-
ented in Table 1. Figure 1 reflects the different scintigraphic
TABLE 2 Results of SPECT imaging in comparison with thoracic radiographs and CT for 39 dogs with thyroid tumors
SPECT











Metastasis 15 14 3 10 1 3 1 2 N/A
No metastasis 20 11 1 8 2 7 1 4 2
Suspicious focus 2 1 N/A 1 N/A 1 N/A 1 N/A
Suspicion
vascular activity
2 2 N/A 1 1 1 1 N/A N/A
Abbreviations: CT, computed tomography; N/A, not applicable; SPECT, single-photon emission computed tomography.
F IGURE 2 99mTcO4 SPECT imaging showing the presence of thoracic metastasis. A, Multiple foci in the caudal right and left lung field. One
focus is located in the midline (arrow); B, Presence of 2 foci in the lung field (arrows), of which 1 is located dorsally to the heart at the midthoracic
level and 1 in the left caudal lung field. Note the pertechnetate activity in the esophagus; C, Presence of foci in the midline of the cranial thorax.
The images on the right are representing the different spatial oriented slices (transverse, dorsal, and sagittal slices). The cursor points to a focus of
increased uptake in the thoracic midline
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characteristics including degree of uptake, uptake pattern, and tumor
circumscription.
Of the 12 dogs with ectopic thyroid tumors, 8 had localized dis-
ease confined to the sublingual region, 1 had localized disease con-
fined to the mediast, and 1 had abnormal radionuclide uptake at the
level of the heart base. Two dogs had multicentric primary tumors;
1 had bilateral thyroid tumors in addition to sublingual ectopic dis-
ease, and 1 had a unilateral thyroid tumor in addition to sublingual
ectopic disease.
There was no significant association between uptake extent and
hormone status (P = .15) or tumor type (P = .27), although the majority
of hyperthyroid dogs (10 of 12 dogs) had increased radionuclide
uptake. Of the 5 dogs with MTCs, 2 showed decreased pertechnetate
uptake, whereas uptake was increased in 2 dogs. In 1 dog, 123I scintig-
raphy was performed before and after administration of recombinant
human TSH, which had increased tumor uptake after recombinant
human TSH injection.
There was a significant association between uptake pattern and
hormone status (P = .009), with a heterogeneous uptake pattern in
88% of the tumors of euthyroid dogs, 62% of tumors of hypothyroid
dogs, and 46% of tumors of hyperthyroid dogs. No significant associa-
tion was found between uptake pattern and tumor type (P = 1.0).
There was a significant association between tumor circumscrip-
tion and hormone status (P = .003), but not tumor type (P = .42). The
majority of tumors (85%) of hypothyroid and hyperthyroid dogs were
well circumscribed, whereas the majority of tumors (60%) of euthyroid
dogs had irregular margins. Of the dogs that showed thoracic metasta-
ses on SPECT imaging, half had irregular tumor margins.
3.3 | SPECT imaging in comparison with thoracic
radiographs and CT
Results of SPECT imaging in comparison with thoracic radiographs
and CT are presented in Table 2. Thoracic SPECT imaging was avail-
able in 39 dogs and identified thoracic metastatic lesions in 15 dogs
(Figure 2). Pulmonary lesions were identified in 6 dogs, whereas
lesions in the thoracic midline were present in 7 dogs. One dog had
both thoracic midline and pulmonary lesions and 1 dog had a lesion at
the level of the scapula based on SPECT imaging. The metastatic
lesions that were identified by thoracic radiography (3 dogs) and CT
(1 dog) in this group were all located in the lung field. The location of
these metastatic lesions was consistent between SPECT and radiogra-
phy, and between SPECT and CT. In 1 dog that had evidence of meta-
static disease on SPECT imaging, both CT and radiographs were
initially negative for thoracic metastases. However, radiologic follow-
up after 12 months revealed the presence of pulmonary metastases.
In addition, repeat scintigraphy (both planar and SPECT imaging)
showed progressive metastatic disease.
In 20 dogs, SPECT did not show signs of intrathoracic metastasis.
In 1 dog that did have radiographic evidence of metastatic disease,
multiple pulmonary nodules were identified. In the 2 dogs with doubt-
ful radiographic findings, CT was negative for metastatic disease. In
1 dog, CT showed metastatic disease (involvement of the cranial
mediastinal and sternal lymph nodes, hepatic metastases, and 2 suspi-
cious pulmonary nodules) that was neither identified on SPECT imag-
ing nor thoracic radiographs. Two CTs were doubtful because they
could not completely exclude the presence of metastatic disease due
to the presence of atelectasis and motion artifact.
In 2 dogs, SPECT imaging showed foci of increased uptake in the
thorax that were suggestive of vascular activity (normal blood pool
activity), although metastatic disease could not be completely excluded.
In 1 of these dogs, CT imaging was available and showed pulmonary
metastases, whereas radiographs showed a suspicious lesion in the
lung field. In 2 dogs, SPECT imaging showed a suspicious focus in the
pulmonary field. In 1 of these dogs, radiographs showed no signs of
metastatic disease. In the other dog, CT was performed, which did not
detect thoracic metastases.
In the majority of dogs, scintigraphy was performed using 99mTcO4.
In 6 dogs, both 99mTcO4 and
123I planar scintigrams were performed,
which showed no differences in tumor uptake or uptake pattern. In
2 of these dogs, thoracic SPECT was performed using both 99mTcO4
F IGURE 3 Planar (99mTcO4) and SPECT (
99mTcO4 and
123I) imaging of a dog with bilateral thyroid tumors. 123I SPECT imaging revealed a
thoracic metastasis that was not clearly identified with 99mTcO4 planar and SPECT imaging
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and 123I. In 1 dog, 123I SPECT imaging revealed a thoracic metastasis
that was not clearly identified with 99mTcO4, whereas thoracic metas-
tases were visible in both scans for the other dog, although better
visualized on 123I SPECT imaging (Figure 3).
3.4 | Follow-up thyroid scintigraphy
Follow-up scintigraphy was available in 14 dogs (all 99mTcO4 scans).
Six dogs had follow-up scintigraphy after thyroidectomy, which showed
no uptake at the level of the surgery site except in 1 dog that showed
remnant tissue after partial hyoidectomy of a sublingual ectopic
tumor. In the remaining 8 dogs, follow-up scintigraphy was available
after initial radioiodine treatment. One dog showed no evidence of
radionuclide uptake in the area of the tumor 6 weeks and 7 months
after radioiodine treatment. A reduction in radionuclide uptake com-
pared with pretreatment images was seen in 5 dogs. No change in
radionuclide uptake was seen in 1 dog, and enlargement of the origi-
nal tumor on follow-up scintigraphy was noted in 1 dog.
4 | DISCUSSION
Literature on planar 99mTcO4 and
123I scintigram findings in dogs with
thyroid neoplasia is scarce, and nearly absent for SPECT imaging,
which is only briefly mentioned as a thyroid imaging technique in
2 articles.4,19 Our study describes planar and SPECT imaging in a large
number of dogs with thyroid tumors and shows that SPECT imaging is
a viable imaging technique to screen for thoracic metastasis. Wider
use of SPECT is recommended complementary to structural imaging
modalities such as CT and thoracic radiography.
Similar to previous studies,8,12,14,21 the majority of dogs in our
study had a heterogeneous uptake pattern. Two uptake patterns in
dogs with thyroid tumors were previously described, differentiating a
well-circumscribed, homogeneous area of uptake (pattern I), and a
poorly circumscribed, heterogeneous area of uptake (pattern II).12
Although the majority of tumors with homogeneous uptake patterns
had well-circumscribed margins in our study, this was not applicable to
all tumors. Moreover, poorly circumscribed margins were only seen in
about half of the tumors with heterogenous uptake. Based on this, the
previously reported classification scheme12 might not be suitable to
describe scintigraphic findings in the majority of thyroid tumors. We
suggest describing thyroid scintigraphic findings by characterization of
uptake, uptake pattern, and tumor circumscription separately, rather
than constraining to fixed combinations of aforementioned features.
In human medicine, thyroid diseases can produce abnormal pat-
terns that could be described as homogeneous or heterogeneous,
increased or decreased, and diffuse or local.13 Areas of focally increased
uptake (hot nodules) are almost always benign (hyperfunctioning
autonomous adenomas), whereas areas of focally decreased uptake
(cold nodules) could reflect malignancy.13,22 This is in contrast to our
findings in dogs, in which most thyroid carcinomas showed (diffusely
or focally) increased radionuclide uptake.
In our study, there was a significant association between uptake
pattern and hormone status, with the majority of euthyroid dogs hav-
ing a heterogeneous uptake at the level of the thyroid tumor. It might
be hypothesized that loss of cellular pertechnetate trapping is a result
from loss of thyroid cell differentiation,23 and that a heterogeneous
uptake pattern is caused by the presence of both differentiated and
dedifferentiated tumor tissue, or both dedifferentiated tumor tissue
and remaining normal thyroid tissue. Euthyroid hormone status could
be maintained in both scenarios. On the contrary, to acquire a hyper-
thyroid hormone status, an adequate amount of well-differentiated
tissue, capable of thyroid hormone production, is required. This could
explain the larger amount of homogeneous uptake patterns in hyper-
thyroid dogs, which is also seen in other studies.12 If the thyroid
tumor destroys enough of the thyroid gland to cause hypothyroidism,
the remaining normal tissue will have increased uptake because of
increased TSH secretion, which could explain the heterogeneous
uptake patterns in hypothyroid dogs.4 On the other hand, a heteroge-
neous uptake pattern could be seen if the dog was previously hypo-
thyroid and the resulting chronic exposure to TSH would cause
excess promotion of residual follicular tissue and formation of thyroid
follicular neoplasia.24 In addition, extensive necrosis and hemorrhage
is present in most thyroid tumors, and these areas are expected to
have decreased radionuclide uptake, possibly contributing to a hetero-
geneous uptake pattern.
Importantly, most of the scintiscans were performed using 99mTcO4.
In 6 dogs, both 99mTcO4 and
123I planar scintigrams were performed.
In contrast to 99mTcO4,
123I is also organified by the thyroid, allowing
for determination of “true” uptake, which could be more reflective of
thyroid physiology.13,14 Although no differences were seen in uptake
or uptake pattern between the 99mTcO4 and
123I scintigrams, it would
be interesting to evaluate 123I scintigram findings in a larger number
of dogs.
A significant association between tumor circumscription and hor-
mone status was found in our study, with well-delineated tumors in
the majority of hyperthyroid and hypothyroid dogs. In a previous
study, 5 out of 6 hyperthyroid dogs showed well-circumscribed
uptake,12 whereas only 1 out of 3 hypothyroid dogs had a well-
delineated tumor. Another study describes irregular margins in 6 out
of 7 masses, but thyroid hormone status is not mentioned in our
study.8 A more recent study suggests different scintigraphic appear-
ances based on tumor type, with a diffuse increased uptake in follicu-
lar tumors or adenomas, a decreased uptake, effacing the normal
thyroid tissue, in stromal tumors, and irregular, heterogeneous uptake
in mixed cell tumors.5 However, in both our study and a previous
study,12 there was no association between uptake pattern and histo-
logic type of the tumor.
In our study, 3 of 5 dogs with MTCs showed increased radionu-
clide uptake, which was an unexpected finding because normal and
malignant parafollicular C-cells do not have the ability to trap iodine.
In 1 dog that was previously described by our research group,25 123I
uptake was present in both the primary tumor and thoracic metasta-
ses. The remaining 4 dogs had 99mTcO4 SPECT imaging performed,
which was suggestive of vascular activity in 2 dogs and negative for
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thoracic metastases in 2 dogs. To the authors' knowledge, radionu-
clide uptake by a medullary carcinoma has only been described in
1 previous report in veterinary medicine.12 In human medicine, trap-
ping of radioiodine and 99mTcO4 has been described,
26,27 although
the mechanism underlying the ability of medullary carcinoma cells
remains unclear. Because MTCs may be difficult to distinguish from
compact FTCs by histopathology, IHC for calcitonin or markers of
neuroendocrine tissue (chromogranin A) is required for their identifi-
cation.2,28 On the other hand, thyroglobulin can be used as a marker
for FTCs. In 1 of the MTCs that showed increased pertechnetate
uptake in our study, IHC was not available, making the diagnosis of
MTC questionable. In the other MCT with increased pertechnetate
uptake, IHC was positive for calcitonin, but thyroglobulin staining was
not performed. The presence of a mixed medullary-follicular thyroid
carcinoma, which has been described as a rare thyroid tumor in
human medicine,29,30 can therefore not be excluded. The same
applies to the MTC that showed 123I uptake; which was positive for
chromogranin A, but had no staining for thyroglobulin performed. Fur-
ther studies, using comprehensive histopathology and IHC to correctly
characterize thyroid tumor type, are needed to evaluate possible
radionuclide uptake by MTCs.
According to a previous study, planar scintigraphy does not
appear to offer any additional benefit, compared to thoracic radiogra-
phy, for detection of pulmonary metastases.12 In our study, only 2 of
29 dogs had radiographic evidence of pulmonary metastases, which is
considerably lower than reported metastatic rates.1-3 One dog, of
which the primary tumor had minimal radionuclide uptake, had radio-
graphic but not scintigraphic evidence of pulmonary metastases. It
was suggested that the lack of trapping function was similar for both
the primary tumor and the metastatic lesion.12 In our study, 1 dog had
radiographic evidence of metastatic disease whereas thoracic SPECT
imaging was negative. The primary tumor of this dog showed a
decreased uptake. However, of the 15 dogs that did show metastases
on SPECT imaging, 7 had an uptake at the level of the primary mass
that was decreased or comparable to the salivary glands, an observa-
tion that has also been described for planar imaging.8 Therefore,
SPECT imaging is valuable for metastasis detection regardless of the
uptake of the primary tumor. A possible explanation for the discrep-
ancy between the uptake at the level of the primary mass and metas-
tases could be that the function of the sodium iodide symporter,
which is responsible for radionuclide uptake, disappears at the level of
the tumor during the course of the disease (loss of differentiation),
whereas it could be preserved at the level of metastases, that may dis-
play a different pattern of expression of thyroid-specific proteins.22,31
Our results showed that SPECT imaging is a viable imaging tech-
nique to screen for thoracic metastasis. Compared to thoracic radiogra-
phy, SPECT imaging appeared to be especially valuable in detection of
thoracic midline lesions. Single-photon emission computed tomography
identified metastatic lesions in 15 dogs, whereas radiographs identified
metastatic disease in only 3 of these dogs. In addition, in most cases of
thyroid tumors, negative SPECT results seemed to be reliable to
exclude metastatic disease. Thoracic CT images were only available for
12 dogs, limiting the possibility to compare SPECT and CT findings.
Although the pattern and localization of abnormal thoracic foci of radio-
iodine uptake were unlikely to be the result of physiologic uptake,
false-positives could not be completely excluded. The use of hybrid
SPECT/CT imaging would improve the accuracy of disease detection,
because the fusion of the SPECT imaging information with the ana-
tomic CT data provides better identification and interpretation of
the foci of pertechnetate/radioiodine uptake, more correct anatomic
localization and characterization, and thus more precise differentia-
tion between physiologic uptake and metastatic lesions.16-18,20,32
Foci corresponding to malignant lesions seen on SPECT/CT in
human patients with differentiated thyroid carcinoma are not always
identified on diagnostic CT, emphasizing the limitations of CT for con-
firming the presence of metastatic disease.17 Although SPECT is widely
used in human medicine, the limited availability in veterinary medicine
is a drawback of this technique.
The main limitation of our study is its lack of consistent imaging.
Thoracic CT images were only available in part of the dogs, precluding
the confirmation or exclusion of the presence of metastatic disease as
diagnosed by SPECT imaging. To definitively confirm the presence of
metastases, necropsy would have been required, which was not per-
formed in the majority of dogs.
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